Detection and quantification of the Abelson tyrosine kinase domains of the bcr-abl gene translocation in chronic myeloid leukaemia using genomic quantitative real-time polymerase chain reaction

Annals of the Academy of Medicine Singapore

Volumn 35, Issue 10, 2006, Pages 680-687

  Gullo, Charles A ^a,b   Chuah, Charles T H ^b   Hwang, William Y K ^b   Teoh, Gerrard K H ^a,b  

^a Singapore Health Services   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Drug resistance; Haematologic neoplasms; Molecular diagnostic techniques; Philadelphia chromosome

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; PROTEIN TYROSINE KINASE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PHILADELPHIA 1 CHROMOSOME; REAL TIME POLYMERASE CHAIN REACTION;

EID: 33751572663     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987;49:127-67.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
3. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Leukemia 1960;132:1497.
4. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining (letter). Nature 1973;243:290-3.
5. Dreazen O, Klisak I, Rassool F, Goldman JM, Sparkes RS, Gale RP. The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia. Oncogene Res 1988;22:167-75.
6. Hagemeijer A. Chromosome abnormalities in CML. Baillieres Clin Haematol 1987;1:963-81.
7. Daley GQ, Ben Neriah Y. Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. Adv Cancer Res 1991;57:151-84.
8. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
9. Groffen J, Heisterkamp N. The BCR/ABL hybrid gene. Baillieres Clin Haematol 1987;1:983-99.
10. Bhatia R, Verfaillie CM. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998;91:3414-22.
11. Buckle AM, Mottram R, Pierce A, Lucas GS, Russell N, Miyan JA, et al. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells. Mol Med 2000;6:892-902.
12. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994;83:1179-87.
13. Peggs K, Mackinnon S. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-50.
14. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.
15. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-8.
16. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
17. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
18. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-34.
19. Kaeda J, Chase A, Goldman JM. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 2002;107:64-75.
20. Chomel JC, Brizard F, Veinstein A, Rivet J, Sadoun A, Kitzis A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000;95:404-8.
21. Kitzis A, Brizard F, Dascalescu C, Chomel JC, Guilhot F, Brizard A. Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission. Leuk Lymphoma 2001;42:933-44.
22. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIPlL1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
23. Deininger MW. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. J Cancer Res Clin Oncol 2004;130:59-72.
24. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905-11.
25. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 2003;17:465-7.
26. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17:481-7.
27. Bumm T, Muller C, Al Ali HK, Krohn K, Shepherd P, Schmidt E, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941-9.
28. Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003;17:634-5.
29. Cherrier-De Wilde S, Rack K, Vannuffel P, Delannoy A, Hagemeijer A. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission. Leukemia 2003;17:2046-8.
30. Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 1999;59:3171-4.
31. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22:176-81.
32. Selden JR, Emanuel BS, Wang E, Cannizzaro L, Palumbo A, Erikson J, et al. Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells. Proc Natl Acad Sci U S A 1983;80:7289-92.
33. Wu SQ, Voelkerding KV, Sabatini L, Chen XR, Huang J, Meisner LF. Extensive amplification of bcr/abl fusion genes clustered on three marker chromosomes in human leukemic cell line K-562. Leukemia 1995;9:858-62.
34. Blagosklonny MV. STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia 2002;16:570-2.
35. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-8.
36. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
37. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001;293:2163.
38. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359:487-91.
39. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
40. Kurzrock R, Kantarjian H, Talpaz M. Chronic myelogenous leukemia in chronic phase. Curr Treat Options Oncol 2001;2:245-52.